Genetic testing in patients with hypertrophic cardiomyopathy

Czech version

Authors: Jiří Bonaventura; Josef Veselka
Authors‘ workplace: Kardiologická klinika 2. LF UK a FN Motol, Praha
Published in: Vnitř Lék 2019; 65(10): 652-658
Category:

Overview

Hypertrophic cardiomyopathy (HCM) is a frequent inherited heart disease with an estimated prevalence of up to 1 in 200 individuals. In the majority of cases, HCM is inherited as an autosomal dominant genetic trait with pathogenic variants detected in sarcomeric proteins. Nevertheless, the genetic basis of HCM is more complex. More than 2 000 mutations in 27 genes have been described in association with HCM. The genetic and allelic heterogeneity makes molecular analysis by conventional methods time-consuming and expensive. Next Generation Sequencing (NGS) based genomic testing allows rapid analysis of a large number of genes or even a whole genome at similar cost and accuracy to conventional sequencing methods. Screening large numbers of genes results in the identification of many genetic variants of uncertain significance and makes the results interpretation difficult. The process of classification the genetic variants is very complex. Genetic screening is an important tool for clinical management of HCM patients and enables mutation-specific confirmatory testing of the appropriate family members. The yield of genetic testing is variable, about 20–40 %. For predicting the diagnostic yield of genetic testing, clinical scoring systems have been developed. Identifying the genetic basis of HCM creates remarkable opportunities to understand how disease develops, and by extension, how to disrupt the disease progression in the future.

Keywords:

Genetics – next generation sequencing – genetic testing – genotype – hypertrophic cardiomyopathy

Sources

Elliott PM, Anastasakis A, Borger M et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J 2014; 35(39): 2733–2779. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehu284>.
Veselka J, Anavekar NS, Charron P. Hypertrophic obstructive cardiomyopathy. Lancet 2017; 389(10075): 1253–1267. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(16)31321–6>.
Richard P, Charron P, Carrier L et al. Hypertrophic cardiomyopathy: Distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 2003;107(17): 2227–2232. Dostupné z DOI: <http://dx.doi.org/10.1161/01.CIR.0000066323.15244.54>. Erratum in Circulation 2004;109(25):3258.
Maron BJ, Doerer JJ, Haas TS et al. Sudden Deaths in Young Competitive Athletes: Analysis of 1866 Deaths in the United States, 1980–2006. Circulation 2009; 119(8): 1085–1092. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.108.804617>.
Semsarian C, Ingles J, Maron MS et al. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol 2015; 65(12): 1249–1254. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2015.01.019>.
Geisterfer-Lowrance AA, Kass S, Tanigawa G et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell 1990; 62(5): 999–1006. Dostupné z DOI: <http://dx.doi.org/10.1016/0092–8674(90)90274-i>.
Ho CY, Charron P, Richard P et al. Genetic advances in sarcomeric cardiomyopathies: State of the art. Cardiovasc Res 2015; 105(4): 397–408. Dostupné z DOI: <http://dx.doi.org/10.1093/cvr/cvv025>.
Ingles J, Burns C, Barratt A et al. Application of Genetic Testing in Hypertrophic Cardiomyopathy for Preclinical Disease Detection. Circ Cardiovasc Genet 2015; 8(6): 852–859. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCGENETICS.115.001093>.
Alfares AA, Kelly MA, McDermott G et al. Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: Expanded panels offer limited additional sensitivity. Genet Med 2015; 17(11): 880–888. Dostupné z DOI: <http://dx.doi.org/10.1038/gim.2014.205>.
Maron BJ, Maron MS, Semsarian C. Genetics of Hypertrophic Cardiomyopathy After 20 Years: Clinical Perspectives. J Am Coll Cardiol 2012; 60(8): 705–715. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2012.02.068>.
Sabater-Molina M, Pérez-Sánchez I, Hernández del Rincón JP et al. Genetics of hypertrophic cardiomyopathy: A review of current state. Clin Genet 2018; 93(1): 3–14. Dostupné z DOI: <http://dx.doi.org/10.1111/cge.13027>.
Online Mendelian Inheritance in Man®. Dostupné z WWW: <https://www.omim.org/>.
Gersh BJ, Maron BJ, Bonow RO et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: A report of the American College of cardiology foundation/American heart association task force on practice guidelines. Circulation 2011; 124(24): e783-e831. Dostupné z DOI: <http://dx.doi.org/10.1161/CIR.0b013e318223e2bd>.
Lopes LR, Syrris P, Guttmann OP et al. Novel genotype-phenotype associations demonstrated by high-throughput sequencing in patients with hypertrophic cardiomyopathy. Heart 2015; 101(4): 294–301. Dostupné z DOI: <http://dx.doi.org/10.1136/heartjnl-2014–306387>.
Walsh R, Buchan R, Wilk A et al. Defining the genetic architecture of hypertrophic cardiomyopathy: re-evaluating the role of non-sarcomeric genes. Eur Heart J 2017; 38(46): 3461–3468. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw603>.
McNally E, Dellefave L. Sarcomere mutations in cardiogenesis and ventricular noncompaction. Trends Cardiovasc Med 2009; 19(1): 17–21. Dostupné z DOI: <http://dx.doi.org/10.1016/j.tcm.2009.03.003>.
Mogensen J, Kubo T, Duque M et al. Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. J Clin Invest 2003; 111(2): 209–216. Dostupné z DOI: <http://dx.doi.org/10.1172/JCI16336>. Erratum in J Clin Invest 2003; 111(6): 925.
Bortot B, Athanasakis E, Brun F et al. High-throughput Genotyping Robot-assisted Method for Mutation Detection in Patients With Hypertrophic Cardiomyopathy. Diagnostic Mol Pathol 2011; 20(3): 175–179. Dostupné z DOI: <http://dx.doi.org/10.1097/PDM.0b013e31820b34fb>.
Fokstuen S, Munoz A, Melacini P et al. Rapid detection of genetic variants in hypertrophic cardiomyopathy by custom DNA resequencing array in clinical practice. J Med Genet 2011; 48(8): 572–576. Dostupné z DOI: <http://dx.doi.org/10.1136/jmg.2010.083345>.
Meder B, Haas J, Keller A et al. Targeted Next-Generation Sequencing for the Molecular Genetic Diagnostics of Cardiomyopathies. Circ Cardiovasc Genet 2011; 4(2): 110–122. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCGENETICS.110.958322>.
IGSR and the 1000 Genomes Project. Dostupné z WWW: <http://www.internationalgenome.org/>.
NHLBI Exome Sequencing Project (ESP). Dostupné z WWW: <http://evs.gs.washington.edu/EVS/>.
Exome Aggregation Consortium. Dostupné z WWW. <http://exac.broadinstitute.org/>.
ClinVar. Dostupné z WWW: <https://www.ncbi.nlm.nih.gov/clinvar>.
Human Gene Mutation Database. Dostupné z WWW: <http://www.hgmd.cf.ac.uk/ac/index.php>.
Richards S, Aziz N, Bale S et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17(5): 405–424. Dostupné z DOI: <http://dx.doi.org/10.1038/gim.2015.30>.
Jensen MK, Havndrup O, Christiansen M et al. Penetrance of hypertrophic cardiomyopathy in children and adolescents: a 12-year follow-up study of clinical screening and predictive genetic testing. Circulation 2013; 127(1): 48–54. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.111.090514>.
Cardoso B, Gomes I, Loureiro P et al. Clinical and genetic diagnosis of familial hypertrophic cardiomyopathy: Results in pediatric cardiology. Rev Port Cardiol 2017; 36(3): 155–165. Dostupné z DOI: <http://dx.doi.org/10.1016/j.repc.2016.09.009>.
Hershberger RE, Givertz MM, Ho CY et al. Genetic Evaluation of Cardiomyopathy – A Heart Failure Society of America Practice Guideline. J Card Fail 2018; 24(5): 281–302. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cardfail.2018.03.004>.
Priori SG, Blomström-Lundqvist C, Mazzanti A et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Europace 2015; 17(11): 1601–87. Dostupné z DOI: <http://dx.doi.org/10.1093/europace/euv319>.
Olivotto I, Girolami F, Ackerman MJ et al. Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Mayo Clin Proc 2008; 83(6): 630–638. Dostupné z DOI: <http://dx.doi.org/10.4065/83.6.630>.
Varnava AM, Elliott PM, Baboonian C et al. Hypertrophic Cardiomyopathy. Circulation 2001; 104(12): 1380–1384. Dostupné z DOI: <http://dx.doi.org/10.1161/hc3701.095952>.
Ho CY. Genetics and clinical destiny: improving care in hypertrophic cardiomyopathy. Circulation 2010; 122(23): 2430–2340; discussion 2440. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.110.978924>.
Maron BJ, Yeates L, Semsarian C. Clinical challenges of genotype positive (+) phenotype negative (-) family members in hypertrophic cardiomyopathy. Am J Cardiol 2011; 107(4): 604–608. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2010.10.022>.
Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol 2012; 60(8): 705–715. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2012.02.068>.
Maron BJ. Clinical Course and Management of Hypertrophic Cardiomyopathy. N Engl J Med 2018; 379(7): 655–668. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMra1710575>.
Charron P, Carrier L, Dubourg O et al. Penetrance of familial hypertrophic cardiomyopathy. Genet Couns 1997; 8(2): 107–114.
Richard P, Charron P, Carrier L et al. Hypertrophic cardiomyopathy: Distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 2003; 107(17): 2227–2232. Dostupné z DOI: <http://dx.doi.org/10.1161/01.CIR.0000066323.15244.54>. Erratum in Circulation 2004; 109(25): 3258.
Amendola LM, Jarvik GP, Leo MC et al. Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium. Am J Hum Genet 2016; 98(6): 1067–1076. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ajhg.2016.03.024>.
Bonaventura J, Norambuena P, Tomašov P et al. The utility of the Mayo Score for predicting the yield of genetic testing in patients with hypertrophic cardiomyopathy. Arch Med Sci 2019; 15(3): 641–649. Dostupné z DOI: <http://dx.doi.org/10.5114/aoms.2018.78767>.
Bos JM, Will ML, Gersh BJ et al. Characterization of a phenotype-based genetic test prediction score for unrelated patients with hypertrophic cardiomyopathy. Mayo Clin Proc 2014; 89(6): 727–737. Dostupné z DOI: <http://dx.doi.org/10.1016/j.mayocp.2014.01.025>.
Murphy SL, Anderson JH, Kapplinger JD et al. Evaluation of the Mayo Clinic Phenotype-Based Genotype Predictor Score in Patients with Clinically Diagnosed Hypertrophic Cardiomyopathy. J Cardiovasc Transl Res 2016; 9(2): 153–161. Dostupné z DOI: <httP://dx.doi.org/10.1007/s12265–016–9681–5>.
Alcalai R, Seidman JG, Seidman CE. Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics. J Cardiovasc Electrophysiol 2008; 19(1): 104–110. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1540–8167.2007.00965.x>.
Mathew J, Zahavich L, Lafreniere-Roula M et al. Utility of genetics for risk stratification in pediatric hypertrophic cardiomyopathy. Clin Genet 2017; 93(2): 310–319. Dostupné z DOI: <http://dx.doi.org/10.1111/cge.13157>.
Lopes LR, Brito D, Belo A et al. Genetic characterization and genotype-phenotype associations in a large cohort of patients with hypertrophic cardiomyopathy – An ancillary study of the Portuguese registry of hypertrophic cardiomyopathy. Int J Cardiol 2019; 278: 173–179. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ijcard.2018.12.012>.
Blankenburg R, Hackert K, Wurster S et al. β-Myosin heavy chain variant Val606Met causes very mild hypertrophic cardiomyopathy in mice, but exacerbates HCM phenotypes in mice carrying other HCM mutations. Circ Res 2014; 115(2): 227–237. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCRESAHA.115.303178>.
Dorn GW, McNally E. Two strikes and you’re out: gene-gene mutation interactions in HCM. Circ Res 2014; 115(2): 208–210. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCRESAHA.114.304383>.
Ingles J, Doolan A, Chiu C et al. Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling. J Med Genet 2005; 42(10): e59. Dostupné z DOI: <http://dx.doi.org/10.1136/jmg.2005.033886>.
Whiffin N, Minikel E, Walsh R et al. Using high-resolution variant frequencies to empower clinical genome interpretation. Genet Med 2017; 19(10): 1151–1158. Dostupné z DOI: <http://dx.doi.org/10.1038/gim.2017.26>.
Rigopoulos AG, Ali M, Abate E et al. Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement. Heart Fail Rev 2019; 24(4):521–533. Dostupné z DOI: <http://dx.doi.org/10.1007/s10741–019–09776–3>.
Brosnan MJ, Rakhit D. Differentiating Athlete’s Heart From Cardiomyopathies – The Left Side. Hear Lung Circ 2018; 27(9): 1052–1062. Dostupné z DOI: <http://dx.doi.org/10.1016/j.hlc.2018.04.297>.
Jiang J, Wakimoto H, Seidman JG et al. Allele-specific silencing of mutant Myh6 transcripts in mice suppresses hypertrophic cardiomyopathy. Science 2013; 342(6154): 111–114. Dostupné z DOI: <http://dx.doi.org/10.1126/science.1236921>.
Cannon L, Yu ZY, Marciniec T et al. Irreversible Triggers for Hypertrophic Cardiomyopathy Are Established in the Early Postnatal Period. J Am Coll Cardiol 2015; 65(6): 560–569. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2014.10.069>.
Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 2014; 157(6): 1262–1278. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cell.2014.05.010>.
Ma H, Marti-Gutierrez N, Park SW et al. Correction of a pathogenic gene mutation in human embryos. Nature 2017; 548(7668): 413–419. Dostupné z DOI: <http://dx.doi.org/10.1038/nature23305>.